×
Do you want to link to this External Site and leave Amgenbd.com?
You will be redirected in 5 seconds.
No, Return to Amgenbd.com
Yes, Leave Amgenbd.com
YOU ARE NOW LEAVING THE AMGENBD WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Atara: Burgeoning Biotech

The Emergence of an Amgen Investment

Atara Biotherapeutics, Inc. is a biopharmaceutical development company focusing on innovative therapies for patients with debilitating diseases. Amgen’s support of this company, from its founding in 2012 to its Initial Public Offering to the treatment of its first patients with ovarian cancer and other solid tumors just two years later, is one example of how Amgen works with investors and innovators at early stages to create value.

October 2012

• Atara is founded by Amgen and Kleiner Perkins Caufield & Byers (KPCB).

• Established with licenses to six Amgen assets in various stages of development.

• Isaac Ciechanover, M.D., a former partner at KPCB, to serve as president and chief executive officer.

June 2013

• Dr. Christopher Haqq, Atara Biotherapeutics’ Chief Medical Officer, presents poster at June 2013 annual meeting of the American Society of Clinical Oncology in Chicago.

December 2013

• Atara secures $38.5 million in initial closings under its Series B financing.

• Excerpt from announcement: “Within only 15 months of its founding, the Atara team initiated a Phase 2 pilot trial of PINTA 745, a myostatin inhibiting peptibody, being investigated as a potential treatment for protein energy wasting (PEW), a form of inflammation, malnutrition and muscle wasting in patients with end-stage renal disease.”

January 2014

• Atara announces second closing of Series B financing, bringing the total raised this round to $52 million.

• Amgen Ventures is among a handful of investors.

• Two lead programs: PINTA 745 and STM 434.

• PINTA 745 is described by Atara as a myostatin inhibiting peptibody in Phase 2 development as a potential treatment for protein energy wasting (PEW), a form of inflammation, malnutrition and muscle wasting in patients with end-stage renal disease.

• STM 434, an inhibitor of activin, is described by Atara as representing a novel targeted approach for the treatment of ovarian cancer as well as other solid tumors.

September 2014

• Atara announces entry into exclusive option agreement with Memorial Sloan Kettering Cancer Center (MSK) for the development and commercialization of allogeneic T-cell therapies for the treatment of certain cancers and persistent viral infections.

October 2014

• Atara announces pricing of initial public offering.

• Shares to begin trading on NASDAQ Global Select Market under the ticker symbol "ATRA."